Trials / Completed
CompletedNCT01370629
Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)
A Prospective Observational Registry Study to Characterise Normal Conditions of Use, Dosing and Safety Following Administration of Vernakalant IV Sterile Concentrate
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,015 (actual)
- Sponsor
- Correvio International Sarl · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This non-interventional prospective study is a post-authorization safety study (PASS) of vernakalant conducted to collect information about normal conditions of use and appropriate dosing, and to quantify possible medically significant risks associated with the use of vernakalant in real-world clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vernakalant | Prescribed at the discretion of the physician in accordance with their usual practice |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2018-04-05
- Completion
- 2018-05-08
- First posted
- 2011-06-10
- Last updated
- 2019-12-30
- Results posted
- 2019-12-30
Locations
6 sites across 6 countries: Austria, Denmark, Finland, Germany, Spain, Sweden
Source: ClinicalTrials.gov record NCT01370629. Inclusion in this directory is not an endorsement.